These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1137 related articles for article (PubMed ID: 10720854)

  • 21. Prospective use of free prostate-specific antigen to avoid repeat prostate biopsies in men with elevated total prostate-specific antigen.
    Morgan TO; McLeod DG; Leifer ES; Murphy GP; Moul JW
    Urology; 1996 Dec; 48(6A Suppl):76-80. PubMed ID: 8973705
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Can free and total prostate specific antigen and prostatic volume distinguish between men with negative and positive systematic ultrasound guided prostate biopsies?
    Prestigiacomo AF; Stamey TA
    J Urol; 1997 Jan; 157(1):189-94. PubMed ID: 8976248
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination and multivariate analysis of PSA-based parameters for prostate cancer prediction.
    Djavan B; Remzi M; Zlotta AR; Seitz C; Wolfram R; Hruby S; Bursa B; Schulman CC; Marberger M
    Tech Urol; 1999 Jun; 5(2):71-6. PubMed ID: 10458658
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml.
    Ornstein DK; Rayford W; Fusaro VA; Conrads TP; Ross SJ; Hitt BA; Wiggins WW; Veenstra TD; Liotta LA; Petricoin EF
    J Urol; 2004 Oct; 172(4 Pt 1):1302-5. PubMed ID: 15371828
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Predictive value of prostate specific antigen density in the detection of prostate cancer in patients with elevated prostate specific antigen levels and normal digital rectal findings or stage A prostate cancer].
    Iwaki H; Kajita Y; Shimizu Y; Yamauchi T
    Hinyokika Kiyo; 2001 Mar; 47(3):169-74. PubMed ID: 11329957
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Diagnostic algorithm based on a multivariate model to reduce the percentage of negative prostatic biopsies in patients with changed PSA or suspicious rectal palpation].
    Valer Algarabel J; Agüera Fernández L; Adot Zurbano JM; Virseda Chamorro M; Marcos Díez J; Gómez López A; Alpuente Román C
    Actas Urol Esp; 2000; 24(7):549-59. PubMed ID: 11011445
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen.
    Luderer AA; Chen YT; Soriano TF; Kramp WJ; Carlson G; Cuny C; Sharp T; Smith W; Petteway J; Brawer MK
    Urology; 1995 Aug; 46(2):187-94. PubMed ID: 7542820
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves.
    Catalona WJ; Richie JP; deKernion JB; Ahmann FR; Ratliff TL; Dalkin BL; Kavoussi LR; MacFarlane MT; Southwick PC
    J Urol; 1994 Dec; 152(6 Pt 1):2031-6. PubMed ID: 7525994
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The use of prostate specific antigen density to improve the sensitivity of prostate specific antigen in detecting prostate carcinoma.
    Bretton PR; Evans WP; Borden JD; Castellanos RD
    Cancer; 1994 Dec; 74(11):2991-5. PubMed ID: 7525040
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The role of the absolute value and "density" of the prostate-specific antigen estimated echographically in the selection of patients to undergo a biopsy in suspected prostatic carcinoma. A comparison between PSA, palpation and echography in 95 patients undergoing echo-guided endorectal prostatic biopsy].
    Di Donna A; Bazzocchi M; Guerra UP; Bendini M; De Biasi F; Caminiti F; Delendi M
    Radiol Med; 1993; 85(1-2):84-9. PubMed ID: 7683136
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate cancer screening in Tyrol, Austria: experience and results.
    Horninger W; Reissigl A; Rogatsch H; Volgger H; Studen M; Klocker H; Bartsch G
    Eur Urol; 1999; 35(5-6):523-38. PubMed ID: 10325519
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination.
    Uzzo RG; Pinover WH; Horwitz EM; Parlanti A; Mazzoni S; Raysor S; Mirchandani I; Greenberg RE; Pollack A; Hanks GE; Watkins-Bruner D
    Urology; 2003 Apr; 61(4):754-9. PubMed ID: 12670560
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Improved discrimination between prostatic carcinoma and benign prostatic hyperplasia by determination of free prostate-specific antigen percentage].
    Wolff JM; Borchers H; Boeckmann W; Habib FK; Jakse G
    Urologe A; 1997 May; 36(3):255-8. PubMed ID: 9265347
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early detection of prostate cancer in Germany: a study using digital rectal examination and 4.0 ng/ml prostate-specific antigen as cutoff.
    Luboldt HJ; Bex A; Swoboda A; Hüsing J; Rübben H;
    Eur Urol; 2001 Feb; 39(2):131-7. PubMed ID: 11223671
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
    Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
    BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of prostate cancer and changes in prostate-specific antigen (PSA) six months after surgery for benign prostatic hyperplasia in patients with elevated PSA.
    Ozden C; Inal G; Adsan O; Yazici S; Ozturk B; Cetinkaya M
    Urol Int; 2003; 71(2):150-3. PubMed ID: 12890951
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Systematic ultrasound guided transrectal core prostate biopsy based on serum level of prostate-specific antigen].
    Yamaguchi S; Baba Y; Naito K
    Hinyokika Kiyo; 1997 Sep; 43(9):641-5. PubMed ID: 9365843
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rationale for using serum prostate-specific antigen (PSA) level and PSA density (PSAD) to detect prostatic malignancy in a country with low prostate cancer incidence.
    Rahardjo D; Kamil ST; Pakasi LS
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():563-70. PubMed ID: 10895211
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Usefulness of the ratio free/total prostate-specific antigen in addition to total PSA levels in prostate cancer screening.
    Reissigl A; Klocker H; Pointner J; Fink K; Horninger W; Ennemoser O; Strasser H; Colleselli K; Höltl L; Bartsch G
    Urology; 1996 Dec; 48(6A Suppl):62-6. PubMed ID: 8973702
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical evaluation of prostate biopsy parameters: gland volume and elevated prostate-specific antigen level.
    Rubens DJ; Gottlieb RH; Maldonado CE; Frank IN
    Radiology; 1996 Apr; 199(1):159-63. PubMed ID: 8633140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 57.